Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis.
Journal
HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
30
10
2019
revised:
16
01
2020
accepted:
02
03
2020
pubmed:
3
4
2020
medline:
26
10
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
The present study aimed to assess the clinical features of patients who received lenvatinib treatment for unresectable hepatocellular carcinoma (HCC). The clinical characteristics, adverse events, and radiological responses were evaluated for 51 consecutive patients. Of the study subjects, 37 patients had Child-Pugh class A (CPA) liver function, and 14 patients had Child-Pugh class B (CPB) liver function. The overall response rates in the CPA and CPB groups were 42.9% and 25.0%, respectively, and disease control rates were 82.9% and 83.3%, respectively, without significant difference (p = 0.2621 and 0.9697). There was no significant difference between CPA and CPB groups regarding the incidence of adverse events, except for hepatic coma. No significant difference was observed in the relative dose intensity between the CPA and CPB groups, for the first month, 1-2 months, or 2-3 months (p = 0.2368, 0.9368, and 0.9293). The comparable outcomes between the CPA and CPB groups suggest the acceptability of lenvatinib treatment in patients with impaired liver function, at least in the acute phase. With careful follow-up, the dose can be relatively intensified, even in patients with impaired liver function and this may contribute to offering comparable treatment.
Sections du résumé
BACKGROUND
The present study aimed to assess the clinical features of patients who received lenvatinib treatment for unresectable hepatocellular carcinoma (HCC).
METHODS
The clinical characteristics, adverse events, and radiological responses were evaluated for 51 consecutive patients.
RESULTS
Of the study subjects, 37 patients had Child-Pugh class A (CPA) liver function, and 14 patients had Child-Pugh class B (CPB) liver function. The overall response rates in the CPA and CPB groups were 42.9% and 25.0%, respectively, and disease control rates were 82.9% and 83.3%, respectively, without significant difference (p = 0.2621 and 0.9697). There was no significant difference between CPA and CPB groups regarding the incidence of adverse events, except for hepatic coma. No significant difference was observed in the relative dose intensity between the CPA and CPB groups, for the first month, 1-2 months, or 2-3 months (p = 0.2368, 0.9368, and 0.9293).
CONCLUSION
The comparable outcomes between the CPA and CPB groups suggest the acceptability of lenvatinib treatment in patients with impaired liver function, at least in the acute phase. With careful follow-up, the dose can be relatively intensified, even in patients with impaired liver function and this may contribute to offering comparable treatment.
Identifiants
pubmed: 32238302
pii: S1365-182X(20)30081-2
doi: 10.1016/j.hpb.2020.03.002
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Phenylurea Compounds
0
Quinolines
0
lenvatinib
EE083865G2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1450-1456Informations de copyright
Copyright © 2020 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.